Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment?

Jeanne M Lusher

doi:10.1055/s-0038-1657619

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1997; 78(01): 726-729
DOI: 10.1055/s-0038-1657619

Disorders of hemostasis in childhood

Schattauer GmbH Stuttgart

Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment?

Jeanne M Lusher

The Children’s Hospital of Michigan, Detroit, Ml, USA

› Institutsangaben

Abstract

als PDF herunterladen

PDF (824 kb)

Referenzen

References
1 Onwuzurike N, Warrier I, Lusher JM. Types of bleeding seen during the first 30 months of life in children with severe haemophilia A and B. Haemophilia 1996; 02: 137-140
2 Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 149: 153-159
3 Ahlberg Å. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965; 77 (Suppl) 07-80
4 Heijnen L, de GrootC, Prevo A. Arthropathy in hemophiliacs. Comparing long term prophylaxis with treatment on demand. pres, at XV Congress. World Federation of Hemophilia: Stockholm, Sweden; 1983 abstract booklet, p. 49
5 Brettler DB, Levine PH. Clinical manifestations and therapy of inherited coagulation factor deficiencies. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 3rd ed. Colman RW, Hirsch J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994. pp 169-183
6 Roberts HR, Hoffman M. Hemophilia and related conditions-inherited deficiencies of prothrombin (factor II), factor V, and factors VII to XII. In: Williams Hematology, 5th ed. Beutler E, Lichtman MA, Coller BS, Kipps TJ. eds. McGraw-Hill; New York, NY: 1995. pp 1413-1439
7 Furie B, Limentani SA, Rosenfield CG. A practical guide to the evaluation and treatment of hemophilia. Blood 1994; 84: 03-09
8 Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 01 (Suppl. 01) 08-13
9 Association of Hemophilia Clinic Directors of Canada. Hemophilia and von Willebrand’s disease 2. Management. Canadian Med Assocn J 1995; 153: 147-157
10 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-135
11 Nilsson I, Berntorp E, Lӧfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe hemophilia A and B. J Intern Med 1992; 232: 25-32
12 Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrate in preventing hemophilic arthropathy. Am J Ped Hematol Oncol 1991; 13: 280-287
13 Ljung RCR, Lindgren A-C, Tengborn L, Petrini P. Issues in prophylaxis for young children in Sweden: the long-term feasibility of venous access. In: Prophylactic treatment of hemophilia A and B: current and future perspectives. New York: Sci and Med; 1994. pp 49-51
14 Berntorp E. Methods of hemophilia care delivery; regular prophylaxis vs episodic treatment. Haemophilia 1995; 1 (Suppl. 01) 03-07
15 Carlsson M, Berntorp E, Bjӧrkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993; 31: 247-252
16 Pettersson H, Gilbert M. Diagnostic Imaging in Hemophilia; Musculoskeletal and other hemorrhagic complications. Springer Verlag; Berlin: 1985. pp 56-65
17 Aronstam A, Arblaster PG, Rainsford SG, Turk P. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33: 81-90
18 Schimpf K, Fischer B, Rothmann P. Die ambulante dauerbehandlung der hämophilie A. Dtsch Med Wochenshr 1976; 101: 141-148
19 Morfini M, Mannucci PM, Mariani G. et al Evolution of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-47
20 van denBergHM, Nieuwenhuis HK, Mauser-Bunschoten EP, Roosendaal G. Hemophilia prophylaxis in the Netherlands. Semin Hematol 1994; 31 (Suppl. 02) 13-15
21 Aledort LM, Haschmeyer RH. Pettersson H and the Orthopaedic Outcome Study Group. A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Intern Med 1994; 236: 391-399
22 The National Hemophilia Foundation. Medical and Scientific Advisory Council recommendations concerning prophylaxis. The National Hemophilia Foundation (110 Greene St., N.Y., N.Y., 10012), Medical Bulletin No. 193, Chapter Advisory No. 197 March 11 1994
23 Nilsson IM, Berntorp E, Ljung R, Lӧfqvist T, Pettersson H. Prophylactic treatment of severe hemophilia A and B can prevent joint disability. Semin Hematol 1994; 31 (Suppl. 02) 05-09
24 Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haac A, Olek K, Tuddenham EGD, Oldenburg J, Haemophilia A. mutation type determines risk of inhibitor formation. Thrombos Haemostas 1995; 74: 1402-1406
25 Aledort LM. Prophylaxis: the next hemophilia treatment (Editorial). J Intern Med 1992; 232: 01-02
26 Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coag Fibrinolysis. 1996; 07 (Suppl. 01) S35-S37
27 Bohn RL, Avom J. Reimbursement for hemophilia in the United States: current policies and future considerations. Semin Hematol 1994; 31 (Suppl. 02) 26-28
28 Steinglass P. Psychosocial issues related to prophylactic therapy for hemophilia. Semin Hematol 1994; 31 (Suppl. 02) 19-25
29 Vora AJ, Lilleyman JS. Vascular access in young hemophiliacs: use of indwelling central venous catheters. Internat J Pediatr Hematol Oncol 1994; 01: 521-527
30 Warrier I, Baird-Cox K, Cygan ML, Lusher JM. Experience with central venous catheters in children with hemophilia. Thrombos Haemostas 1993; 69: 854 (abstract)
31 Reed CR, Sessler CN, Glauser RL, Phelan BA. Central venous catheter infections: concepts and controversies. Intensive Care Med 1995; 21: 177-183
32 Ljung R, Petrini P, Lindgren A-K, Berntorp E. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992; 81: 918-920
33 Raad II, and Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-210
34 Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-978
35 Ljung RCR, Lindgren A-C, Tengborn L, Petrini P. The feasibility of long-term venous access in children with hemophilia. Semin Hematol 1994; 31 (Suppl. 02) 16-18
36 Manco-Johnson MJ, Nuss R, Geraghty S, Funk S. A prophylactic program in the United States: experience and issues. Semin Hematol 1994; 31 (Suppl. 02) 10-12
37 Nuss R, Kilcoyne R, Geraghty S, Wiedel J, Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr 1993; 123: 388-392